Regulatory approval

Published by the Health Service Executive. Approved

First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults

This is written in the approval document.

Reimbursement

ODMS

Citation

Pembrolizumab 400mg Monotherapy, 2024, version number 13, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6389/558_v12b_Pembrolizumab_400mg_monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) dMMR Colorectal Adenocarcinoma Pembrolizumab
HSE (1) MSI-H Colorectal Adenocarcinoma Pembrolizumab